Inotek Pharmaceuticals – Inotek Announces Top-Line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma - Trial Did Not Achieve Superiority to Placebo at All 12 Time Points- - Diurnal IOP Reduction of 4.25mmHg at Three Months With Trabodenoson 6% Once-A-Day Dose, Statistically Superior to Placebo - - Safety and Tolerability Similar to Placebo- - Conference Call Scheduled for 8:30am EST Today - (January 3rd, 2017)
Lexington, MA January 3, 2017 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced top-line results of MATrX-1, the first pivotal Phase 3 trial of trabodenoson for the treatment of primary open-angle glaucoma (POAG) or ocular hypertension (OHT). The trial did not achieve its primary endpoint of superiority in reduction of intraocular pressure (IOP) compared with placebo at all 12 time points. This was, in part, due to a placebo response that was 2-3 mmHg greater than that observed in Phase 2. Trabodenoson, the Companys lead clinical candidate, is a first-in-class, highly selective adenosine mimetic targeting the A1 subreceptor. Trabodenoson lowers IOP by augmenting the eyes natural function of the trabecular meshwork, the primary outflow pathway for aqueous humor and a site of pathology in glaucoma.